




Instance: composition-en-4a09b3a8552105810368cbf52100627e
InstanceOf: CompositionUvEpi
Title: "Composition for deferiprone Package Leaflet"
Description:  "Composition for deferiprone Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/18/1310/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp4a09b3a8552105810368cbf52100627e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - deferiprone"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Deferiprone Lipomed is and what it is used for </li>
<li>What you need to know before you take Deferipone Lipomed </li>
<li>How to take Deferiprone Lipomed </li>
<li>Possible side effects  </li>
<li>How to store Deferiprone Lipomed </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What deferiprone is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What deferiprone is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Deferiprone Lipomed contains the active substance deferiprone. Deferiprone Lipomed is an iron 
chelator, a type of medicine that removes excess iron from the body. </p>
<p>Deferiprone Lipomed is used to treat iron overload caused by frequent blood transfusions in patients 
with thalassaemia major when current chelation therapy is contraindicated or inadequate. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take deferiprone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take deferiprone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Deferiprone Lipomed 
- if you are allergic to deferiprone or any of the other ingredients of this medicine (listed in 
section 6); 
- if you have a history of repeated episodes of neutropenia (low white blood cell (neutrophil) 
count); 
- if you have a history of agranulocytosis (very low white blood cell (neutrophil) count); 
- if you are currently taking medicines known to cause neutropenia or agranulocytosis (see  Other 
medicines and Deferiprone Lipomed ); 
- if you are pregnant or breast-feeding. </p>
<p>Warnings and precautions<br />
The most serious side effect that may occur while taking Deferiprone Lipomed is a very low white 
blood cell (neutrophil) count. This condition, known as severe neutropenia or agranulocytosis, has 
occurred in 1 to 2 out of 100 people who have taken deferiprone in clinical trials. Because white blood 
cells help to fight infection, a low neutrophil count may place you at risk of developing a serious and 
potentially life-threatening infection. To monitor for neutropenia, your doctor will ask you to have a 
blood test (to check your white blood cell count) performed regularly, as frequently as every week, 
while you are being treated with Deferiprone Lipomed. It is very important for you to keep all of these 
appointments. Please refer to the patient card provided in the folding box. If you get any symptoms of 
infection such as fever, sore throat or flu-like symptoms, immediately seek medical attention. Your 
white blood cell count must be checked within 24 hours in order to detect potential agranulocytosis. </p>
<p>If you are HIV positive or if your liver or kidney function is severely impaired, your doctor may 
recommend additional tests. </p>
<p>Your doctor will also ask you to come in for tests to monitor body iron load. In addition, he or she 
might ask you to undergo liver biopsies. </p>
<p>Talk to your doctor or pharmacist before taking Deferiprone Lipomed. </p>
<p>Other medicines and Deferiprone Lipomed 
Do not take medicines known to cause neutropenia or agranulocytosis (see  Do not take Deferiprone 
Lipomed ). Tell your doctor or pharmacist if you are taking, have recently taken, or might take any 
other medicines, including medicines obtained without a prescription. </p>
<p>Do not take aluminium-based antacids at the same time as taking Deferiprone Lipomed. </p>
<p>Please consult with your doctor or pharmacist before taking vitamin C with Deferiprone Lipomed. </p>
<p>Pregnancy and breast-feeding 
Deferiprone Lipomed may cause harm to unborn babies when used by pregnant women. Deferiprone 
Lipomed must not be used during pregnancy unless clearly necessary. If you are pregnant or you 
become pregnant during treatment with Deferiprone Lipomed, get medical advice immediately. </p>
<p>Both female and male patients are recommended to take special precautions in their sexual activity if 
there is any possibility for pregnancy to occur. Women of childbearing potential are recommended to 
use effective contraception during treatment with Deferiprone Lipomed and for 6 months after the last 
dose. Men are recommended to use effective contraception during treatment and for 3 months after the 
last dose. This should be discussed with your doctor.<br />
Do not use Deferiprone Lipomed if you are breast-feeding. Please refer to the patient card provided in 
the folding box. </p>
<p>Driving and using machines 
This medicine has no or negligible influence on the ability to drive and use machinery. </p>
<p>Deferiprone Lipomed contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet and that is to say essentially 
 sodium-free . </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take deferiprone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take deferiprone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. The amount of Deferiprone Lipomed that you take will depend on your weight. 
The usual dose is 25 mg/kg, 3 times per day, for a total daily dose of 75 mg/kg. The total daily dose 
should not exceed 100 mg/kg. Take your first dose in the morning. Take your second dose midday. 
Take your third dose in the evening. Deferiprone Lipomed can be taken with or without food; 
however, you may find it easier to remember to take Deferiprone Lipomed if you take it with your 
meals. </p>
<p>If you take more Deferiprone Lipomed than you should 
There are no reports of acute overdose with deferiprone. If you have accidentally taken more than the 
prescribed dose, you should contact your doctor. </p>
<p>If you forget to take Deferiprone Lipomed 
Deferiprone Lipomed will be most effective if you do not miss any doses. If you do miss one dose take 
it as soon as you remember and take your next dose at its regularly scheduled time. If you miss more 
than one dose do not take a double dose to make up for forgotten individual doses, just continue with 
your normal schedule. Do not change your daily dose without first talking to your doctor. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The most serious side effect of Deferiprone Lipomed is a very low white blood cell (neutrophil) count. 
This condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of people who have taken deferiprone in clinical trials. A low white blood cell count can be associated 
with a serious and potentially life-threatening infection. Report immediately to your doctor any 
symptoms of infection such as: fever, sore throat or flu-like symptoms. </p>
<p>Very common side effects (may affect more than 1 in 10 people):</p>
<ul>
<li>abdominal pain </li>
<li>nausea </li>
<li>vomiting </li>
<li>reddish/brown discolouration of urine </li>
</ul>
<p>If you experience nausea or vomiting, it may help to take your Deferiprone Lipomed with some food. 
Discoloured urine is a very common effect and is not harmful. </p>
<p>Common side effects (may affect up to 1 in 10 people):</p>
<ul>
<li>low white blood cell count (agranulocytosis and neutropenia) </li>
<li>headache </li>
<li>diarrhoea </li>
<li>increase in liver enzymes </li>
<li>fatigue </li>
<li>increase in appetite </li>
</ul>
<p>Not known (frequency cannot be estimated from the available data):</p>
<ul>
<li>allergic reactions including skin rash or hives </li>
</ul>
<p>Events of joint pain and swelling ranged from mild pain in one or more joints to severe disability. In 
most cases, the pain disappeared while patients continued taking deferiprone. </p>
<p>Additional side effects in children 
In post-marketing experience with deferiprone, neurological disorders (such as tremors, walking 
disorders, double vision, involuntary muscle contractions, problems with movement coordination) 
have been reported in children who had been voluntarily prescribed more than double the maximum 
recommended dose of 100 mg/kg/day for several years and have also been observed in children with 
standard doses of deferiprone. They recovered from these symptoms after discontinuation of 
deferiprone. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store deferiprone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store deferiprone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not store above 25 C. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on the blister after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Deferiprone Lipomed contains<br />
The active substance is deferiprone. Each film-coated tablet contains 500 mg deferiprone. </p>
<p>The other ingredients are: </p>
<p>Tablet core: hypromellose, croscarmellose sodium (see section 2  Deferiprone Lipomed contains 
sodium ), silica, colloidal anhydrous, microcrystalline cellulose, magnesium stearate </p>
<p>Coating: hypromellose, macrogol 6 000, titanium dioxide </p>
<p>What Deferiprone Lipomed looks like and contents of the pack 
Deferiprone Lipomed 500 mg film-coated tablets are white to off-white, glossy surface, oval film-
coated tablets. The tablets are scored and breakable in half. Deferiprone Lipomed is packaged in 
blisters. One pack contains 100 film-coated tablets. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Lipomed GmbH 
Hegenheimer Strasse 2 
79576 Weil am Rhein 
Germany 
Phone number: +49 7621 1693 Fax number: +49 7621 1693 Electronic mail: lipomed@lipomed.com </p>
<p>This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-4a09b3a8552105810368cbf52100627e
InstanceOf: CompositionUvEpi
Title: "Composition for deferiprone Package Leaflet"
Description:  "Composition for deferiprone Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/18/1310/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp4a09b3a8552105810368cbf52100627e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - deferiprone"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Deferiprone Lipomed  </li>
<li>Sådan skal du tage Deferiprone Lipomed </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What deferiprone is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What deferiprone is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Deferiprone Lipomed indeholder det aktive stof deferipron. Deferiprone Lipomed er en jernchelator, 
dvs. en type medicin, der fjerner overskydende jern fra kroppen. </p>
<p>Deferiprone Lipomed bruges til at behandle jernophobning som følge af hyppige blodtransfusioner hos 
talassæmi-patienter, hvor nuværende kelationsterapi er kontraindiceret eller utilstrækkelig.  </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take deferiprone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take deferiprone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Deferiprone Lipomed 
 
hvis du er overfølsom over for deferipron eller et af de øvrige indholdsstoffer i denne medicin 
(angivet i punkt 6) 
 
hvis du har haft gentagne episoder med neutropeni (et lavt antal hvide blodlegemer (neutrofiler) 
 
hvis du har haft agranulocytose (et meget lavt antal hvide blodlegemer (neutrofiler). 
 
hvis du tager medicin, der vides at kunne forårsage neutropeni eller agranulocytose (se punktet 
"Anden medicin og Deferiprone Lipomed") 
 
hvis du er gravid eller ammer. </p>
<p>Advarsler og forsigtighedsregler 
De alvorligste bivirkninger, som kan fremkomme, mens du tager Deferiprone Lipomed, er et meget 
lavt antal hvide blodlegemer (neutrofiler)). Denne tilstand, som kaldes svær neutropeni eller 
agranulocytose, optrådte hos 1 til 2 ud af 100 personer, som tog deferiproni kliniske studier. Da hvide 
blodlegemer hjælper med at bekæmpe infektioner, vil et lavt antal neutrofiler udsætte dig for en risiko 
for at udvikle en alvorlig eller evt. livstruende infektion. Din læge vil bede dig om at få taget en 
blodprøve for at undersøge for neutropeni (kontrollere antallet af hvide blodlegemer) regelmæssigt, så 
ofte som hver uge, mens du behandles med Deferiprone Lipomed. Det er meget vigtigt, at du 
overholder alle disse aftaler. Se patientkortet i foldeæsken. Fortæl det straks til din læge, hvis der 
fremkommer symptomer på infektion, såsom feber, ondt i halsen eller influenzalignende symptomer. 
Søg straks læge, hvis du får symptomer på infektion som f.eks. feber, ondt i halsen eller 
influenzalignende symptomer. Antallet af hvide blodlegemer skal kontrolleres inden for et døgn for at 
opdage potentiel agranulocytose. </p>
<p>Hvis du er hiv-positiv, eller hvis din lever- eller nyrefunktion er kraftigt nedsat, kan din læge anbefale 
yderligere undersøgelser. </p>
<p>Din læge vil også bede dig møde til undersøgelser for at kontrollere din krops jernbelastning. 
Derudover kan han eller hun måske bede dig få taget nogle leverbiopsier. </p>
<p>Tal med din læge eller apotektet, inden du begynder at tage Deferiprone Lipomed. </p>
<p>Brug af anden medicin sammen med Deferiprone Lipomed<br />
Du må ikke tage medicin, der vides at forårsage neutropeni eller agranulocytose (se pkt. "Tag ikke 
Deferiprone Lipomed"). Fortæl det altid til lægen eller på apoteket, hvis du tager anden medicin, for 
nylig har taget anden medicin eller planlægger at tage anden medicin. Dette gælder også medicin, som 
ikke er købt på recept. </p>
<p>Tag ikke aluminiumbaserede syreneutraliserende midler, samtidig med at du tager Deferiprone 
Lipomed. </p>
<p>Kontakt din læge eller apoteket, før du tager ascorbinsyre (C-vitamin) sammen med Deferiprone 
Lipomed. </p>
<p>Graviditet og amning 
Deferiprone Lipomed kan forårsage skade på ufødte børn, hvis det bruges af gravide kvinder. 
Deferiprone Lipomed må ikke bruges under graviditeten, medmindre det er klart nødvendigt. Hvis du 
er gravid eller du bliver gravid under behandlingen med Deferiprone Lipomed, skal du straks søge 
medicinsk rådgivning. </p>
<p>Det anbefales, at både kvindelige og mandlige patienter tager særlige sikkerhedsforanstaltninger under 
deres seksuelle aktivitet, hvis der er nogen mulighed for, at en graviditet kan opstå: Det anbefales, at 
kvinder i den fertile alder bruger effektive præventionsmidler under behandlingen med Deferiprone 
Lipomed, og i 6 måneder efter den sidste dosis. Det anbefales, at mænd bruger effektive 
præventionsmidler under behandlingen, og i 3 måneder efter den sidste dosis. Dette skal drøftes med 
lægen. Brug ikke Deferiprone Lipomed, hvis du ammer. Referér venligst til det patientkort, der er 
påsat denne æske. </p>
<p>Brug ikke Deferiprone Lipomed, hvis du ammer. Referér venligst til informationskortet til 
patient/plejer i foldeæsken. </p>
<p>Trafik- og arbejdssikkerhed 
Dette lægemiddel påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene 
maskiner. </p>
<p>Deferiprone Lipomed indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet og er således stort set 
natriumfrit. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take deferiprone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take deferiprone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid denne medicin nøjagtigt efter lægens anvisning. Spørg lægen eller apoteket, hvis du er i tvivl. 
Den mængde Deferiprone Lipomed, du tager, afhænger af din vægt. Den normale dosis er 25 mg/kg, 
3 gange daglig, for en total daglig dosis på 75 mg/kg. Den totale daglige dosis bør ikke overstige 
100 mg/kg. Tag den første dosis om morgenen. Tag den anden dosis midt på dagen. Tag den tredje 
dosis om aftenen. Deferiprone Lipomed kan tages med eller uden mad; det kan dog være lettere for dig 
at huske at tage, hvis du tager det sammen med dine måltider. </p>
<p>Hvis du har taget for meget Deferiprone Lipomed 
Der foreligger ingen indberetninger om akut overdosering meddeferipron. Hvis du ved en fejltagelse 
har indtaget mere end den anbefalede dosis, skal du kontakte din læge. </p>
<p>Hvis du har glemt at tage Deferiprone Lipomed<br />
Deferiprone Lipomed er mest effektivt, hvis du ikke springer nogen doser over. Hvis du har sprunget 
en dosis over, skal du tage den så snart, du kommer i tanker om det, og så tage den næste dosis til det 
normalt planlagte tidspunkt. Hvis du springer mere end én dosis over, må du ikke tage en dobbeltdosis 
som erstatning for glemte enkeltdoser, du skal blot fortsætte efter den normale behandlingsplan. 
Foretag ikke ændringer i den daglige dosering, uden først at have talt med lægen. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Den alvorligste bivirkning ved Deferiprone Lipomed er et meget lavt antal hvide blodlegemer 
(neutrofiler). Denne tilstand, der betegnes som alvorlig neutropeni eller agranulocytose, er 
forekommet hos 1 til 2 ud af 100 patienter, som har taget Deferiprone Lipomed i studier med patienter. 
Et lavt antal hvide blodlegemer kan være forbundet med en alvorlig og måske livstruende infektion. 
Kontakt straks din læge, hvis du har symptomer på infektion såsom feber, ondt i halsen eller 
influenzalignende symptomer. </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 behandlede):</p>
<ul>
<li>mavesmerter </li>
<li>kvalme </li>
<li>opkastning </li>
<li>rødbrun misfarvning af urinen </li>
</ul>
<p>Hvis du får kvalme eller kaster op, kan det måske hjælpe at indtage Deferiprone Lipomed<br />
sammen med mad. Misfarvet urin er en meget almindelig bivirkning og er ikke skadelig. </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 behandlede):</p>
<ul>
<li>lavt antal hvide blodlegemer (agranulocytose og neutropeni) </li>
<li>hovedpine </li>
<li>diarré </li>
<li>stigning i leverenzymer </li>
<li>træthed </li>
<li>forøget appetit </li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke skønnes fra de tilgængelige data):</p>
<ul>
<li>allergiske reaktioner som f.eks. hududslæt eller nældefeber </li>
</ul>
<p>Ledsmerte og hævelse spændende fra let smerte i et eller flere led til alvorlig funktionsnedsættelse. I 
de fleste tilfælde forsvandt smerten, selv om patienterne fortsatte med at tage deferipron. </p>
<p>Hos børn kan endvidere ses følgende bivirkninger 
Der er efter markedsføring af deferipron rapporteret neurologiske forstyrrelser (såsom tremor, 
gangforstyrrelser, dobbeltsyn, ufrivillige muskelsammentrækninger, problemer med 
bevægelseskoordination) er rapporteret hos børn, som igennem flere år frivilligt har fået ordineret 
mere end 2 gange den maksimalt anbefalede dosis på 100 mg/kg/dag, og er også observeret hos børn 
ved standarddoser af deferipron. Disse symptomer forsvandt, når børnene ophørte med at tage 
deferipron. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store deferiprone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store deferiprone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Må ikke opbevares ved temperaturer over 25 ºC. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisterpakningen efter Exp. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Deferiprone Lipomed indeholder: 
Aktivt stof: deferipron. Hver filmovertrukket tablet indeholder 500 mg deferipron. </p>
<p>Øvrige indholdsstoffer: </p>
<p>Tabletkerne: Hypromellose 
Croscarmellosenatrium (se punkt 2 "Deferiprone Lipomed indeholder natrium") 
Silica, kolloid vandfri 
Mikrokrystallinsk cellulose 
Magnesiumstearat </p>
<p>Tabletovertræk: Hypromellose, macrogol 6 000, titandioxid. </p>
<p>Udseende og pakningsstørrelser 
Deferiprone Lipomed 500 mg tabletter er hvide til off-white, blanke, ovale filmovertrukne tabletter. 
Tabletterne er forsynet med rille og kan brækkes over i to dele. Deferiprone Lipomed er pakket i 
blisterpakninger. En pakke indeholder 100 filmovertrukne tabletter. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Indehaver af markedsføringstilladelse: 
Lipomed GmbH 
Hegenheimer Strasse 2 
79576 Weil am Rhein 
Tyskland 
Tlf.: +49 7621 1693 Faxnr.: +49 7621 1693 E-mail: lipomed@lipomed.com </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Du kan finde yderligere information om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-4a09b3a8552105810368cbf52100627e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for deferiprone Package Leaflet for language en"
Description: "ePI document Bundle for deferiprone Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-4a09b3a8552105810368cbf52100627e"
* entry[0].resource = composition-en-4a09b3a8552105810368cbf52100627e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4a09b3a8552105810368cbf52100627e"
* entry[=].resource = mp4a09b3a8552105810368cbf52100627e
                            
                    
Instance: bundlepackageleaflet-da-4a09b3a8552105810368cbf52100627e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for deferiprone Package Leaflet for language da"
Description: "ePI document Bundle for deferiprone Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-4a09b3a8552105810368cbf52100627e"
* entry[0].resource = composition-da-4a09b3a8552105810368cbf52100627e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4a09b3a8552105810368cbf52100627e"
* entry[=].resource = mp4a09b3a8552105810368cbf52100627e
                            
                    



Instance: mp4a09b3a8552105810368cbf52100627e
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Deferiprone Lipomed 500 mg film-coated tablets"
Description: "Deferiprone Lipomed 500 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/18/1310/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Deferiprone Lipomed 500 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 4a09b3a8552105810368cbf52100627eListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "deferiprone"

* status = #current
* mode = #working

* title = "List of all ePIs associated with deferiprone"

* subject = Reference(mp4a09b3a8552105810368cbf52100627e)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#deferiprone "deferiprone"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-4a09b3a8552105810368cbf52100627e) // deferiprone en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-4a09b3a8552105810368cbf52100627e) // deferiprone da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-4a09b3a8552105810368cbf52100627e
InstanceOf: List

* insert 4a09b3a8552105810368cbf52100627eListRuleset
    